Velafermin improves gastrointestinal mucositis following irinotecan treatment in tumor-bearing DA rats.
Mucositis is a common, costly and unpleasant side effect of cancer chemotherapy and radiotherapy. Velafermin (FGF-20) has shown the potential to reduce these side effects. Irinotecan is a chemotherapeutic agent which is commonly used in solid tumors, and causes GI mucositis manifested by severe diarrhea. Therefore the primary aim of this study was to investigate whether velafermin reduces the GI mucositis induced by irinotecan. The secondary aim was to test varying schedules of administration of velafermin. Groups of tumor-bearing DA rats (6 per group) were treated with varying doses (4, 8 or 16 mg/kg) of velafermin intraperitoneally either prior to, prior to and during, or after chemotherapy treatment. Rats received a single dose of 200 mg/kg irinotecan intraperitoneally. Rats were monitored closely for the incidence and severity of diarrhea and mortality before being killed 192 h following treatment. Mortality, diarrhea and histopathology were assessed throughout the gastrointestinal tract. Severe or moderate diarrhea occurred in approximately 40% of rats treated with irinotecan alone. This was associated with a 50% mortality rate 96 h following chemotherapy. Velafermin administered at 16 mg/kg prior to irinotecan improved gastrointestinal mucositis as measured by reduced diarrhea and mortality following irinotecan chemotherapy in the DA rat. Rats that received velafermin prior to, or prior to and during irinotecan treatment did develop severe or moderate diarrhea, however it occurred later, in fewer rats and was not associated with mortality. Other dosing regimens were not as effective. This has important implications for the use of velafermin in GI mucositis in humans, and should be further studied.
Gibson
Rachel J
RJ
Department of Medical Oncology, The Ropl Adelaide Hospital, North Terrace, Adelaide 5000 South Australia, Australia. rachel.gibson@adelaide.edu.au
Stringer
Andrea M
AM
Bowen
Joanne M
JM
Logan
Richard M
RM
Yeoh
Ann S-J
AS
Burns
Jaimi
J
Alvarez
Enrique
E
Keefe
Dorothy M K
DM
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001835:Body Weight / Q000187:drug effects; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives*; D003967:Diarrhea / Q000139:chemically induced; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D005759:Gastroenteritis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D000077146:Irinotecan; D052016:Mucositis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D011919:Rats, Inbred Strains
D000972:Antineoplastic Agents, Phytogenic; C416003:FGF20 protein, human; D005346:Fibroblast Growth Factors; D000077146:Irinotecan; D002166:Camptothecin